Bleomycin induces IL-8 and ICAM-1 expression in microvascular pulmonary endothelial cells

Falk Fichtner1, Roland Koslowski, Antje Augstein

  • 1Institute of Anatomy, Medical Faculty Carl Gustav Carus, University of Technology Dresden, Germany.

Insights

Bleomycin (BLM) triggers inflammation in lung microvascular cells by activating p38 MAPK, increasing IL-8 and ICAM-1. This contributes to lung fibrosis, involving both p38 MAPK-dependent and independent pathways.

Area of Science:

  • Pulmonary Medicine
  • Cell Biology
  • Molecular Biology

Background:

  • Bleomycin-induced lung inflammation can lead to pulmonary fibrosis.
  • Understanding early pathomechanisms is crucial for developing treatments.

Purpose of the Study:

  • To investigate the in vitro effects of bleomycin (BLM) on human pulmonary microvascular endothelial cells (HMVEC-L).
  • To elucidate the role of p38 MAPK in BLM-induced inflammatory responses.

Main Methods:

  • Primary human pulmonary microvascular endothelial cells (HMVEC-L) were exposed to BLM.
  • Immunoblotting was used to detect p38 MAPK phosphorylation.
  • Interleukin-8 (IL-8) and intercellular adhesion molecule-1 (ICAM-1) expression were measured via ELISA and real-time PCR.
  • The effect of a p38 MAPK inhibitor (SB 203580) was evaluated.

Main Results:

  • BLM induced p38 MAPK phosphorylation in HMVEC-L.
  • BLM increased IL-8 and ICAM-1 expression at both protein and mRNA levels.
  • SB 203580 inhibited BLM-induced IL-8 upregulation but not ICAM-1 upregulation.
  • These findings suggest both p38 MAPK-dependent and independent mechanisms are involved.

Conclusions:

  • BLM induces pro-inflammatory molecule expression in pulmonary microvascular endothelium.
  • These responses may contribute to early lung inflammation and subsequent fibrosis.
  • p38 MAPK plays a role in BLM-induced IL-8 expression, but other pathways are also involved in BLM's effects on pulmonary microvasculature.

Related Concept Videos